Solid Biosciences reports positive interim data from Duchenne gene therapy trial

March 11, 2026 1:01 PM

Solid Biosciences Inc. (NASDAQ: SLDB) reported interim positive results from its Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a gene ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found